当前位置： SCI文献检索 > REVISTA DE NEUROLOGIA期刊下所有文献 > [Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases].

[Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases].

Abstract：

INTRODUCTION:The inmuno checkpoints inhibitors are new revolutionary treatment for many neoplastic diseases in advanced stadium. There are described several types of neurological complications induced by nivolumab: polyneuropathy, seizures, radiculitis and myasthenia gravis disease. CASE REPORT:A 65 years old man with metastatic lung adenocarcinoma who presented myasthenia gravis disease induced by avelumab therapy with good response to treatment with pyridostigmine and withdrawal of avelumab. CONCLUSIONS:The exact mechanism by which this drug induces myasthenia gravis is still unknown and there is probably a different pathophysiological process to idiopathic myasthenia gravis. An important fact is the variability in the time of onset of myasthenia gravis after initiating treatment with inmuno checkpoints inhibitors. From the clinical point of view, most of the reported cases appeared with a generalized form of myasthenia gravis with bulbar involvement and later developed ophthalmoparesis and fluctuating palpebral ptosis. Our case as well as the review of the previous literature can be useful to alert the clinical neurologist about the possibility of the development of immune-mediated cases of this nature induced by the treatment with avelumab in clinical practice as well as to guide its clinical, prognostic and clinical characteristics. TREATMENT: TITLE:Miastenia grave inducida por tratamiento con inhibidores del punto de control inmunologico: primer caso secundario a avelumab y revision de casos previamente publicados. :Introduccion. Los farmacos inhibidores del punto de control inmunologico han supuesto una revolucion en el tratamiento de varios procesos neoplasicos en estadio avanzado. Sin embargo, se han descrito numerosas complicaciones neurologicas, entre las que se encuentran polineuropatias, crisis epilepticas, radiculitis y miastenia grave. Caso clinico. Varon de 65 años con adenocarcinoma de pulmon en estadio IV en tratamiento con avelumab que desarrolla una miastenia grave ocular seropositiva, con buena respuesta a la piridostigmina y retirada de la medicacion. Conclusiones. El mecanismo exacto por el cual el avelumab induce una miastenia grave aun se desconoce, y probablemente existe un proceso fisiopatologico diferente al de la miastenia grave idiopatica. Un dato importante es la variabilidad en cuanto al tiempo de aparicion de la miastenia grave despues de iniciar el tratamiento con inhibidores del punto de control inmunologico. Desde el punto de vista clinico, la mayoria de los casos descritos comenzo con una forma de miastenia grave generalizada con afectacion bulbar que posteriormente desarrollo oftalmoparesia y ptosis palpebral fluctuante. Este caso, asi como la revision de la bibliografia, puede ser util para alertar al neurologo clinico sobre la posibilidad del desarrollo de cuadros inmunomediados de esta naturaleza inducidos por el tratamiento con avelumab en la practica clinica y para orientar sus caracteristicas clinicas, pronosticas y de tratamiento.

journal_name

Rev Neurol

journal_title

Revista de neurologia

authors

Reyes-Bueno JA,Rodriguez-Santos L,Serrano-Castro PJ

doi

10.33588/rn.6808.2018497

subject

Has Abstract

pub_date

2019-04-16 00:00:00

pages

333-338

issue

eissn

0210-0010

issn

1576-6578

pii

rn2018497

journal_volume

pub_type

杂志文章,评审

在线工具

[Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases].